Cantargia AB (SE:CANTA)

:CANTA

CANTA

Cantargia AB

RESEARCH TOOLSreports

Want to see SE:CANTA full AI Analyst Report?

Cantargia AB (CANTA) Price & Analysis

3 Followers

CANTA Stock Chart & Stats

kr4.07

-kr0.02(-1.25%)

At close: Mar 06 4:00 PM EST

kr4.07

-kr0.02(-1.25%)

Day’s Range― - ―

52-Week Rangekr1.00 - kr6.59

Previous CloseN/A

Volume611.88K

Average Volume (3M)1.42M

Market Cap

kr935.28M

Enterprise Valuekr653.46M

Total Cash (Recent Filing)kr281.82M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)7.1

Beta0.83

Next Earnings

May 26, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding248,611,650

10 Day Avg. Volume1,074,033

30 Day Avg. Volume1,417,172

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)3.91

Price to Sales (P/S)3.28

P/FCF Ratio6.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr14.00

Price Target Upside243.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.63

Revenue Forecast (FY)kr2.20M

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementAnalyst notes that nadunolimab is positioned for a pivotal pancreatic cancer study, and progression through regulatory and financing milestones could significantly de-risk the program and support upside in valuation.

Mechanism And Indication ExpansionAnalyst suggests that nadunolimab's IL1RAP-targeting mechanism may prime tumor environments to improve responses to checkpoint inhibitors, creating potential to expand use into additional cancer types.

Partnerships And FinancingAnalyst highlights that the CAN10 acquisition by a major pharmaceutical company validates the IL1RAP approach and delivered non-dilutive financing plus structured future payments, enabling reinvestment in other pipeline assets.

Bears Say

Colorectal Cancer Immunotherapy ResistanceAnalyst cautions that the targeted colorectal cancer population has historically been non-responsive to immunotherapy, which raises the evidentiary bar for nadunolimab to show clear clinical benefit in that indication.

Cantargia AB News

Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB, with...

3d ago

Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial

Cantargia AB ( ($SE:CANTA) ) has shared an announcement. Cantargia has reported early data from an ongoing Phase...

4d ago

Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026

Cantargia AB ( ($SE:CANTA) ) has issued an update. Cantargia will present the design and supporting preclinical data...

13d ago

Cantargia convenes 2026 AGM with focus on continuity in board

An update from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia AB has called its annual general...

14d ago

Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer

Cantargia AB ( ($SE:CANTA) ) just unveiled an update. Cantargia has reported new preclinical data showing that a...

1M ago

Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference

Cantargia AB ( ($SE:CANTA) ) has provided an update. Cantargia AB will engage in one-on-one investor and partner...

2M ago

Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference

Cantargia AB ( ($SE:CANTA) ) has provided an announcement. Cantargia AB will participate in TD Cowen’s 46th Annual...

2M ago

Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside

Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB and keeping the price target...

2M ago

Cantargia Highlights Pipeline Progress in 2025 Year-End Report

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia’s year-end report for January to December 2025 outlines...

2M ago

Cantargia Sets Date for 2025 Annual Results and Investor Presentation

An announcement from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia will publish its annual results for...

3M ago

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?

Cantargia AB lowest stock price was kr1.00 and its highest was kr6.59 in the past 12 months.

What is Cantargia AB’s market cap?

Cantargia AB’s market cap is kr935.28M.

When is Cantargia AB’s upcoming earnings report date?

Cantargia AB’s upcoming earnings report date is May 26, 2026 which is in 26 days.

How were Cantargia AB’s earnings last quarter?

Cantargia AB released its earnings results on Feb 20, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.19 by kr0.06.

Is Cantargia AB overvalued?

According to Wall Street analysts Cantargia AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cantargia AB pay dividends?

Cantargia AB does not currently pay dividends.

What is Cantargia AB’s EPS estimate?

Cantargia AB’s EPS estimate is -0.18.

How many shares outstanding does Cantargia AB have?

Cantargia AB has 248,611,650 shares outstanding.

What happened to Cantargia AB’s price movement after its last earnings report?

Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.19. Following the earnings report the stock price went down -11.485%.

Which hedge fund is a major shareholder of Cantargia AB?

Currently, no hedge funds are holding shares in SE:CANTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cantargia AB

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

Cantargia AB (CANTA) Earnings & Revenues

Historic Earnings Reports

CANTA Stock 12 Month Forecast

Average Price Target

kr14.00

▲(243.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","15":"kr15","3.75":"kr3.75","7.5":"kr7.5","11.25":"kr11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.19,4.944615384615385,5.69923076923077,6.453846153846154,7.208461538461538,7.9630769230769225,8.717692307692307,9.472307692307691,10.226923076923075,10.98153846153846,11.736153846153844,12.490769230769228,13.245384615384616,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.19,4.944615384615385,5.69923076923077,6.453846153846154,7.208461538461538,7.9630769230769225,8.717692307692307,9.472307692307691,10.226923076923075,10.98153846153846,11.736153846153844,12.490769230769228,13.245384615384616,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.19,4.944615384615385,5.69923076923077,6.453846153846154,7.208461538461538,7.9630769230769225,8.717692307692307,9.472307692307691,10.226923076923075,10.98153846153846,11.736153846153844,12.490769230769228,13.245384615384616,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.43,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.272,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.406,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.235,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.225,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.185,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >